Paper Details

  1. Home
  2. Paper Details

A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.

Author: JennerPeter

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A2A receptor antagonists are being explored as a nondopaminergic approach to managing Parkinson's disease (PD). A2A receptors are localized in basal ganglia, and antagonists have shown effectiveness in reversing motor deficits in animal models of PD. The selective A2A antagonist KW6002 reversed motor disability and increased locomotor activity in primates without inducing dyskinesia. The findings suggest potential for A2A antagonists as a monotherapy or in combination with existing PD therapies.
Paper Details　
Original Abstract of the Article :
The future management of Parkinson's disease (PD) requires pharmacologic agents that do not lose efficacy with disease progression or induce dyskinesia and that are free of other dopaminergic side effects. A2A receptor antagonists may provide an opportunity to introduce nondopaminergic management of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1212/01.wnl.0000095209.59347.79

データ提供：米国国立医学図書館（NLM）

A2A Antagonists: A Novel Approach to Parkinson's Disease

Parkinson's disease, a debilitating neurodegenerative disorder, poses a significant challenge to researchers and clinicians. This research explores the potential of A2A receptor antagonists, a new class of drugs, as a non-dopaminergic therapy for Parkinson's disease. This research is like discovering a hidden oasis in the vast desert of neurological disorders.

A Promising New Frontier for Parkinson's Treatment

The study demonstrates that A2A antagonists, specifically KW6002, show promising results in animal models of Parkinson's disease, reducing motor deficits and enhancing the effects of existing therapies without inducing dyskinesia. This research opens new avenues for treating Parkinson's disease, offering a potential alternative to existing therapies with fewer side effects.

A Hopeful Outlook for Parkinson's Patients

This research offers a ray of hope for Parkinson's patients, suggesting a potential for new and effective treatment options. The research, like a well-placed oasis in the desert, offers a potential source of relief and improved quality of life for those living with this debilitating condition.

Dr.Camel's Conclusion

This study suggests that A2A antagonists hold promising potential for treating Parkinson's disease. It presents a new avenue for exploration and research, potentially leading to more effective and tolerable treatments for those living with this challenging condition. Just as a desert traveler seeks a reliable source of water, researchers continue to seek new and innovative solutions for Parkinson's disease.

Date :
  1. Date Completed 2004-02-11
  2. Date Revised 2019-05-14
Further Info :

Pubmed ID

14663007

DOI: Digital Object Identifier

10.1212/01.wnl.0000095209.59347.79

Related Literature

Article Analysis
・Side Effects of istradefylline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.